BioCryst Pharma (BCRX) PT Raised to $16 at RBC Capital; Sees Continued Upside
Tweet Send to a Friend
RBC Capital analyst Brian Abraham raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $16.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




